CytoDyn Inc., a biotechnology company focusing on the development of new therapies for combating infection with immune deficiency viruses, announced that A. Bruce Montgomery, M.D. has been appointed to the board of directors effective September 27.
According to a release, Dr. Montgomery is a biotech entrepreneur with a background in product development and clinical studies, currently holding the position of Chief Executive Officer of Cardeas Pharma Corp. Before joining Cardeas Pharma Corp. in 2010, Dr. Montgomery founded and was the Chief Executive Officer of Corus Pharma, Inc., a development stage pharmaceutical company, from 2001 until 2006. In 2006, Gilead acquired Corus Pharma, Inc., and Dr. Montgomery continued at Gilead, serving as Senior Vice President, Respiratory Therapeutics, from 2006 until 2010. Additionally, he previously held positions in clinical development with PathoGenesis Corp. and Genentech.
Dr. Montgomery is a board member of Alder Biotherapeutics and a Trustee for the Washington State Life Sciences Discovery Fund. He has previously served on the boards of ZymoGenetics, Inc., Pacific Science Center, and the Washington State Biotechnology BioMedical Association.
"The Company welcomes Dr. Montgomery to our board of directors," said Nader Pourhassan, CytoDyn's President and CEO. "His extensive pharmaceutical research, development and patent experience, as well as his skills in fundraising and entrepreneurship, will help propel CytoDyn in future endeavors."
CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of HIV.
((Comments on this story may be sent to firstname.lastname@example.org))